Hide metadata

dc.date.accessioned2022-08-08T15:47:54Z
dc.date.available2022-08-08T15:47:54Z
dc.date.created2022-05-28T15:08:53Z
dc.date.issued2022
dc.identifier.citationHjell, Gabriela Szabo, Attila Mørch-Johnsen, Lynn Egeland Holst, Rene Tesli, Natalia Bell, Christina Fischer-Vieler, Thomas Werner, Maren Caroline Frogner Lunding, Synve Hoffart Ormerod, Monica Bettina E. Greenwood Johansen, Ingrid Torp Dieset, Ingrid Djurovic, Srdjan Melle, Ingrid Ueland, Thor Andreassen, Ole Steen, Nils Eiel Haukvik, Unn Kristin Hansen . Interleukin-18 signaling system links to agitation in severe mental disorders. Psychoneuroendocrinology. 2022, 140:105721, 1-8
dc.identifier.urihttp://hdl.handle.net/10852/94840
dc.description.abstractObjective Agitation is a challenging clinical feature in severe mental disorders, but its biological correlates are largely unknown. Inflammasome-related abnormalities have been linked to severe mental disorders and implicated in animal models of agitation. We investigated if levels of circulating inflammasome-related immune markers were associated with agitation in severe mental disorders. Methods Individuals with a psychotic or affective disorder (N = 660) underwent blood sampling and clinical characterization. Plasma levels of interleukin (IL)‐18, IL-18 binding protein (IL-18BP), IL-18 receptor 1 (IL-18R1), IL-18 receptor accessory protein (IL-18RAP), and IL-1 receptor antagonist (IL-1RA) were measured. Agitation levels were estimated with the Positive and Negative Syndrome Scale Excited Component. Multiple linear- and logistic regression were used to investigate the associations between agitation and the immune markers, while controlling for confounders. The influence of psychotic and affective symptoms was assessed in follow-up analyses. Results Agitation was positively associated with IL-18BP (β = 0.13, t = 3.41, p = 0.0007) after controlling for multiple confounders, including BMI, smoking, medication, and substance use. Adjustment for psychotic, manic, and depressive symptoms did not affect the results. There were no significant associations between agitation and the other investigated immune markers (IL-1RA (β = 0.06, t = 1.27, p = 0.20), IL-18 (β = 0.05, t = 1.25, p = 0.21), IL-18R1 (β = 0.04, t = 1.01, p = 0.31), IL-18RAP (odds ratio = 0.96, p = 0.30)). In a subsample (N = 463), we also adjusted for cortisol levels, which yielded unaltered results. Conclusion Our findings add to the accumulating evidence of immune system disturbances in severe mental disorders and suggest the IL-18 system as a part of the biological correlate of agitation independent of affective and psychotic symptoms.
dc.languageEN
dc.rightsAttribution 4.0 International
dc.rights.urihttps://creativecommons.org/licenses/by/4.0/
dc.titleInterleukin-18 signaling system links to agitation in severe mental disorders
dc.title.alternativeENEngelskEnglishInterleukin-18 signaling system links to agitation in severe mental disorders
dc.typeJournal article
dc.creator.authorHjell, Gabriela
dc.creator.authorSzabo, Attila
dc.creator.authorMørch-Johnsen, Lynn Egeland
dc.creator.authorHolst, Rene
dc.creator.authorTesli, Natalia
dc.creator.authorBell, Christina
dc.creator.authorFischer-Vieler, Thomas
dc.creator.authorWerner, Maren Caroline Frogner
dc.creator.authorLunding, Synve Hoffart
dc.creator.authorOrmerod, Monica Bettina E. Greenwood
dc.creator.authorJohansen, Ingrid Torp
dc.creator.authorDieset, Ingrid
dc.creator.authorDjurovic, Srdjan
dc.creator.authorMelle, Ingrid
dc.creator.authorUeland, Thor
dc.creator.authorAndreassen, Ole
dc.creator.authorSteen, Nils Eiel
dc.creator.authorHaukvik, Unn Kristin Hansen
cristin.unitcode185,50,0,0
cristin.unitnameDet medisinske fakultet
cristin.ispublishedtrue
cristin.fulltextoriginal
cristin.qualitycode2
dc.identifier.cristin2027884
dc.identifier.bibliographiccitationinfo:ofi/fmt:kev:mtx:ctx&ctx_ver=Z39.88-2004&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.jtitle=Psychoneuroendocrinology&rft.volume=140:105721&rft.spage=1&rft.date=2022
dc.identifier.jtitlePsychoneuroendocrinology
dc.identifier.volume140:105721
dc.identifier.startpage1
dc.identifier.endpage8
dc.identifier.doihttps://doi.org/10.1016/j.psyneuen.2022.105721
dc.identifier.urnURN:NBN:no-97375
dc.type.documentTidsskriftartikkel
dc.type.peerreviewedPeer reviewed
dc.source.issn0306-4530
dc.identifier.fulltextFulltext https://www.duo.uio.no/bitstream/handle/10852/94840/1/article92722.pdf
dc.type.versionPublishedVersion


Files in this item

Appears in the following Collection

Hide metadata

Attribution 4.0 International
This item's license is: Attribution 4.0 International